The Bispecific antibodies market has been gaining traction over the years owing to its wide applications in cancer treatment. Bispecific antibodies are artificially created antibodies that have a potential to bind with two or more different antigens simultaneously. These antibodies have been developed to redirect T cells or redirect other immune cells like natural killer cells to engage and destroy cancer cells. Bispecific antibodies offer more targeted and potentially more efficacious therapies than conventional monoclonal antibodies.
The global bispecific antibodies market is estimated to be valued at US$ 41.08 Mn in 2024 and is expected to exhibit a CAGR of 29% over the forecast period of 2023 to 2030.
Key Takeaways
Key players operating in the bispecific antibodies are Amgen, Inc., Bayer AG, Dow Pharmaceutical Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F. Hoffmann-La Roche AG. These key players are investing heavily in R&D activities to develop novel bispecific antibody therapeutics and filed for new patents. The growing prevalence of cancer across the globe is propelling the demand for bispecific antibodies. As per WHO, cancer burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. Technological advancements such as bispecific antibody generation platforms like Knobs-into-holes, CrossMab CH3 domain exchange and Combodies are helping in efficient production of bispecific antibodies at large scale.
Market Trends
First, the trend of novel bispecific antibodies in clinical pipeline continues to increase. As of 2021, over 140 bispecific antibodies were in clinical development across various therapeutic areas including oncology. Second, Asia Pacific region is emerging as highly lucrative market due to growing geriatric population and increasing spending on healthcare infrastructure.
Market Opportunities
One major opportunity is repurposing of approved bispecific antibodies for new cancer indications. For example, Blincyto, approved for ALL is under clinical trials for other B-cell malignancies. Second opportunity lies in the development of next-generation bispecific antibodies using novel formats like DVD-Ig and dual variable domain immunoglobulin. These new formats promise to improve stability, solubility and safety profile of bispecific antibodies.
Impact of COVID-19 on Bispecific Antibodies Market Growth
The COVID-19 pandemic impacted the Bispecific Antibodies market positively. During the pandemic, the focus of players shifted towards research and development of antibodies targeting SARS-CoV-2. This led to increased funding and fast-track approvals for clinical trials of COVID-19 treatments. At the same time, lockdowns disrupted supply chains in 2020. This caused delays in manufacturing and shipping of bispecific antibodies in clinical development and commercialization. With rapid approvals, bamlanivimab and etesevimab reduced hospitalization risk for COVID-19 patients. This reinforced the importance of immunotherapy using bispecific antibodies.
Going forward, to sustain revenue growth post-pandemic, companies must focus on expanding their pipeline across oncology and other therapeutic areas. Partnerships and contract manufacturing agreements can ensure smooth supply. Regulators can prioritize review of bispecific antibodies indicated for complex diseases. As the pandemic threat recedes, demand may increase for non-COVID bispecific antibody therapies. Progress in manufacturing technology will boost large-scale production required to meet this demand. Additionally, investments on clinical research will be important to evaluate long-term efficacy and safety of COVID-19 treatments to establish them as a treatment option for future outbreaks.
Geographical Regions with Highest Bispecific Antibodies Market Value
North America accounts for the largest share of global bispecific antibodies market value, driven by favorable reimbursement policies and presence of key market players in the US. Advanced healthcare infrastructure, high adoption of novel immunotherapies, and large cancer patient pool support market growth in the region. Europe is the second largest regional market, with major European countries contributing significantly. The Asia Pacific region is projected to be the fastest growing market during the forecast period, with China and India representing major opportunities. This is attributed to rising healthcare spending, increasing disposable income, growing cancer incidence, and expanding biopharmaceutical industry in the Asia Pacific region.
Fastest Growing Regional Market for Bispecific Antibodies
The Asia Pacific region is expected to witness the highest growth in the bispecific antibodies market during the forecast period. Factors such as increasing patient affordability, rising healthcare spending, expanding biopharmaceutical industry and clinical trial activities in Asia Pacific economies are contributing to market growth. Moreover, collaborations between global pharmaceutical companies and local clinical research organizations are facilitating drug development and market access. Countries such as China and India with rapidly developing healthcare infrastructure and growing cancer incidence present immense opportunities. Initiatives by these governments to promote biologics manufacturing will aid regional market expansion. Therefore, Asia Pacific represents the fastest growing as well as most lucrative geographical market for bispecific antibodies globally.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
